Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
JAZZ [NASD]
Jazz Pharmaceuticals Public Limited Company
Index- P/E117.48 EPS (ttm)1.22 Insider Own4.00% Shs Outstand59.45M Perf Week1.18%
Market Cap8.52B Forward P/E14.14 EPS next Y10.14 Insider Trans-9.34% Shs Float57.33M Perf Month-3.24%
Income80.20M PEG5.72 EPS next Q1.91 Inst Own89.20% Short Float2.96% Perf Quarter1.23%
Sales923.10M P/S9.23 EPS this Y-19.10% Inst Trans0.08% Short Ratio2.05 Perf Half Y-9.90%
Book/sh21.34 P/B6.72 EPS next Y25.71% ROA3.30% Target Price178.13 Perf Year101.75%
Cash/sh4.23 P/C33.89 EPS next 5Y20.53% ROE6.50% 52W Range70.41 - 176.60 Perf YTD13.24%
Dividend- P/FCF31.56 EPS past 5Y20.00% ROI13.30% 52W High-18.84% Beta0.80
Dividend %- Quick Ratio2.00 Sales past 5Y66.80% Gross Margin88.50% 52W Low103.55% ATR5.72
Employees815 Current Ratio2.20 Sales Q/Q25.80% Oper. Margin24.80% RSI (14)43.24 Volatility3.63% 3.85%
OptionableYes Debt/Eq0.96 EPS Q/Q-322.50% Profit Margin8.70% Rel Volume0.87 Prev Close147.95
ShortableYes LT Debt/Eq0.95 EarningsAug 04 Payout0.00% Avg Volume824.85K Price143.32
Recom1.80 SMA20-4.75% SMA50-0.92% SMA2007.78% Volume715,951 Change-3.13%
09-May-14Reiterated R. F. Lafferty Neutral $140 → $130
17-Apr-14Initiated Canaccord Genuity Buy $163
07-Mar-14Resumed Barclays Overweight $200
26-Feb-14Reiterated Stifel Buy $145 → $195
14-Jan-14Reiterated UBS Buy $130 → $164
14-Jan-14Downgrade R. F. Lafferty Buy → Neutral $140
06-Dec-13Reiterated UBS Buy $110 → $130
25-Nov-13Reiterated FBR Capital Outperform $105 → $198
25-Nov-13Reiterated Barclays Overweight $112 → $130
13-Nov-13Reiterated R. F. Lafferty Buy $102 → $118
30-Oct-13Initiated FBR Capital Outperform $105
13-Sep-13Reiterated UBS Buy $87 → $98
22-Aug-13Initiated R. F. Lafferty Buy $102
07-Aug-13Reiterated UBS Buy $80 → $87
07-Aug-13Reiterated Cantor Fitzgerald Buy $86 → $97
07-Aug-13Reiterated Barclays Overweight $70 → $85
31-May-13Initiated Stifel Buy $80
11-Mar-13Initiated Cantor Fitzgerald Buy $86
27-Feb-13Reiterated UBS Buy $64 → $67
23-May-12Initiated Oppenheimer Outperform $66
23-Jul-14 09:05PM  Are P/E Ratios Leading You Away From Your Biggest Winners? at Seeking Alpha
22-Jul-14 04:25PM  Jazz Pharmaceuticals/Concert Pharmaceuticals Start Study Zacks
04:05PM  Jazz Pharmaceuticals to Report 2014 Second Quarter Financial Results on August 5, 2014 PR Newswire
21-Jul-14 04:05PM  Jazz Pharmaceuticals and Concert Pharmaceuticals Provide a Phase 1 Clinical Trial Update on JZP-386 Business Wire
01:52PM  Your Best Wealth-Building Choice From Today's Top Market-Maker Price Range Forecasts at Seeking Alpha
01:02PM  3 Stocks Moving The Health Care Sector Upward at TheStreet
14-Jul-14 06:56PM  Irish Stocks Come To Prominence As Taxes Stay Low at Investor's Business Daily
10-Jul-14 12:07PM  Market Slides On European Bank Worries; Gold Stocks Rise at Investor's Business Daily
08:20AM  The Zacks Analyst Blog Highlights: Regado Biosciences, Jazz Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi and Amgen Zacks
09-Jul-14 11:14AM  Salix Pharma Stock Falls Despite Tax-Inversion Deal at Investor's Business Daily
10:40AM  Concert Pharmaceuticals' Shares Slip Despite Favorable FDA Meeting Zacks
08:15AM  Biotech Stock Roundup: Regado Plunges on Study Update, Jazz Gains on Product Acquisition Deal Zacks
08-Jul-14 04:10PM  Raptor Pharmaceuticals CEO to Retire, Appoints Successor Zacks
06:07AM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Other Events EDGAR Online
07-Jul-14 06:18PM  Jazz, Novo Among Medicals Showing Healthy Action at Investor's Business Daily
01:41PM  Stocks Add To Losses; TAL Education Bucks Weakness at Investor's Business Daily
03-Jul-14 06:26PM  Salix, Jazz Lead As Drugmakers Pace IBD 50 For Week at Investor's Business Daily
06:26PM  Salix, Jazz Lead As Drugmakers Pace IBD 50 For Week at Investor's Business Daily
04:10PM  Jazz Pharmaceuticals to Buy Rights to Defibrotide, Shares Up Zacks
08:09AM  Jazz Pharmaceuticals Public Limited Company (JAZZ) in Focus: Stock Moves 6.9% Higher Zacks
02-Jul-14 04:17PM  Stocks End Mixed In Light Trade As Jobs Report Looms at Investor's Business Daily +6.97%
03:09PM  Stocks Nearly Flat In Quiet Trading With 1 Hour To Go at Investor's Business Daily
02:41PM  Watch Out: Barbarians At The Gate For Jazz Pharmaceuticals (JAZZ) at TheStreet
01:54PM  Jazz Pharma Buys Out Rights To Newly Acquired Drug at Investor's Business Daily
08:12AM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exh EDGAR Online
08:00AM  Jazz Pharmaceuticals Announces Agreement To Acquire Rights To Defibrotide In The Americas From Sigma-Tau Pharmaceuticals, Inc. PR Newswire
24-Jun-14 10:28AM  Of These 3 Battleground Biotech Stocks, 1 Is a Buy
23-Jun-14 06:14AM  Momentum bulls return to Jazz optionMONSTER
06:14AM  Momentum bulls return to Jazz
21-Jun-14 10:34AM  The 3 Best Tax Havens for Health Care Companies at Motley Fool
10:34AM  The 3 Best Tax Havens for Health Care Companies
19-Jun-14 06:50PM  Lightning Round: Chiptole, Gilead & more at CNBC
06:50PM  Lightning Round: Chiptole, Gilead & more
05:02PM  Is This Jazz Pharmaceuticals' Worst Nightmare? at Motley Fool
05:02PM  Is This Jazz Pharmaceuticals' Worst Nightmare?
18-Jun-14 06:34PM  M&A Activity Helps Fuel Healthy Action In Drugmakers at Investor's Business Daily
06:34PM  M&A Activity Helps Fuel Healthy Action In Drugmakers
09:42AM  Why Jazz Pharmaceuticals Is an Attractive Buyout Candidate at Motley Fool
09:42AM  Why Jazz Pharmaceuticals Is an Attractive Buyout Candidate
16-Jun-14 05:45PM  Mid-June Equities With Best Wealth-Building Odds, Big Rates Of Gain In Next 6 Months at Seeking Alpha
12-Jun-14 05:00PM  Stephen Mandels Lone Pine Capital sells its shares in Dollar Tree Market Realist
05:00PM  Stephen Mandels Lone Pine Capital sells its shares in Dollar Tree
01:00PM  Lone Pine Capital buys a new stake in Jazz Pharmaceuticals Market Realist
01:00PM  Lone Pine Capital buys a new stake in Jazz Pharmaceuticals
11-Jun-14 01:00PM  Lone Pine Capital buys a new position in LPL Financial Holdings Market Realist
10-Jun-14 03:37PM  Must-know update: Lone Pine Capitals positions in 1Q 2014 Market Realist
05-Jun-14 05:56PM  Positive Phase IIb Data from Jazz Pharma Zacks
05:56PM  Positive Phase IIb Data from Jazz Pharma
04-Jun-14 09:00AM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
09:00AM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Change in Directors or Principal Officers
02-Jun-14 07:18PM  See Which Stocks This $23 Billion Winner Bought at Motley Fool
07:18PM  See Which Stocks This $23 Billion Winner Bought
05:00PM  Jazz Pharmaceuticals Conference Call at 2014 SLEEP Meeting scheduled for 5:00 pm ET today CCBN
02:41PM  Jazz Pharmaceuticals says all endpoints met in JZP-110 Phase 2b study theflyonthewall.com
02:40PM  Jazz Pharmaceuticals Presents JZP-110 Phase 2b Data For The Treatment Of EDS Symptoms In Adults With Narcolepsy PR Newswire
02:14PM  Jazz Pharmaceuticals Conference Call at 2014 SLEEP Meeting scheduled for 5:00 pm ET today CCBN
27-May-14 04:48PM  Market Wrap For May 27: S&P 500 Closes At New Record High After Holiday Weekend Benzinga +5.14%
04:21PM  Nasdaq Leads Indexes; S&P 500 Scores Record High at Investor's Business Daily
04:05PM  Jazz Pharmaceuticals To Present Data On Compound In Sleep Pipeline During APSS Annual SLEEP Meeting PR Newswire
08:55AM  The Dangers of Chasing Hopeful Merger and Buyout Stocks at 24/7 Wall St.
23-May-14 11:12AM  Jazz Pharmaceuticals price target lowered to $151 from $182 at Cantor at theflyonthewall.com
21-May-14 11:45AM  Insider Trading Alert - CYBX, JAZZ And EA Traded By Insiders at TheStreet
20-May-14 09:31AM  2 Reasons to Consider Jazz Pharmaceuticals plc at Motley Fool
19-May-14 04:53PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
02:21PM  Correction: Jazz Pharmaceuticals was not downgraded at Argus at theflyonthewall.com
02:00PM  Jazz Pharmaceuticals names Russell cox as COO at theflyonthewall.com
02:00PM  Jazz Pharmaceuticals Names Russell J. Cox To Position Of Chief Operating Officer PR Newswire
01:58PM  Jazz Pharmaceuticals downgraded to Hold from Buy at Argus at theflyonthewall.com
16-May-14 01:04PM  JAZZ PHARMACEUTICALS PLC Financials EDGAR Online Financials
10:12AM  Jazz Pharmaceuticals management to meet with Guggenheim at theflyonthewall.com
14-May-14 02:09PM  Five Star Biotech Stock Watch: Jazz Pharmaceuticals Benzinga
10:32AM  Stocks Open On A Soft Note; Sears, Kate Spade, Coty Jump at Investor's Business Daily
13-May-14 06:15PM  Jazz Pharmaceuticals Announces Participation in Two Investor Conferences PR Newswire
12-May-14 10:21AM  Ariad Pharmaceuticals, Inc Earnings: Cloudy Future Drains Enthusiasm at Motley Fool
09-May-14 04:34PM  Stocks Close Higher After Late Boost; Air Lease Gains at Investor's Business Daily
11:48AM  Stocks Fall Moderately; Nasdaq Nears Long-Term Support at Investor's Business Daily
11:06AM  Jim Cramer's Stop Trading: Jazz Pharmaceuticals Faces Music at TheStreet
09:41AM  Stocks to Watch: Gap, Hilton Worldwide, Ralph Lauren at The Wall Street Journal
09:11AM  Stock Futures Point Lower; Ubiquiti, Jazz Under Pressure at Investor's Business Daily
09:01AM  Health Care Stocks to Watch Today: Amarin Corporation plc, Jazz Pharmaceuticals, and Vanda Pharmaceuticals at Motley Fool
08:40AM  Earnings Up at Jazz Pharma, Guidance Reiterated Zacks
07:54AM  Early movers: AAPL, CBS, OMC, PUB, MT, TSLA & more at CNBC
07:38AM  Jazz Pharmaceuticals growth story 'very much intact,' says Piper Jaffray at theflyonthewall.com
06:18AM  Jazz Pharmaceuticals price target lowered to $165 from $195 at Citigroup at theflyonthewall.com
08-May-14 09:50PM  Jazz Pharmaceuticals Public Limited's (JAZZ) CEO Bruce Cozadd on Q1 2014 Results - Earnings Call Transcript at Seeking Alpha
06:35PM  Valeant Sales Miss, Q1 Earnings Beat With Allergan Eyed Investor's Business Daily
04:30PM  Jazz Pharmaceuticals Earnings Call scheduled for 4:30 pm ET today CCBN
04:24PM  Jazz Pharmaceuticals sees FY14 adjusted EPS $8.00-$8.25, consensus $8.20 at theflyonthewall.com
04:23PM  Jazz Pharmaceuticals reports Q1 adjusted EPS $1.61, consensus $1.79 at theflyonthewall.com
04:16PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EDGAR Online
04:05PM  Jazz Pharmaceuticals Announces First Quarter 2014 Financial Results PR Newswire
03:58PM  After-hours buzz: CBS, Gap, GrubHub & more at CNBC
01:34PM  Stocks Hold Solid Gains; WhiteWave Surges On Earnings at Investor's Business Daily
09:02AM  Today's Top Health Care Stocks to Watch: Depomed Inc., Dendreon Corp., and Jazz Pharmaceuticals at Motley Fool
07:34AM  Jazz Pharmaceuticals Earnings Call scheduled for 4:30 pm ET today CCBN
07:07AM  Q1 2014 Jazz Pharmaceuticals Earnings Release - After Market Close CCBN
07-May-14 03:36PM  Topping Process Continues in the Nasdaq Composite and Other Major Indices at Minyanville
03-May-14 08:02AM  Ubiquiti, Avis Budget Among 5 IBD 50 Stocks Reporting at Investor's Business Daily
02-May-14 02:11PM  AstraZeneca Nixes New Bid As Pfizer Woos British PM at Investor's Business Daily
28-Apr-14 01:13PM  A Wall Street Transcript Interview with Boris Peaker, Ph.D., Executive Director and Senior Analyst with Oppenheimer & Co. Covering the Biotechnology Sector: Pricing Power for Novel Biotech Drug Therapies Despite Obamacare Wall Street Transcript
Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Its products comprise Xyrem for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment and prevention of VOD, a potentially life-threatening complication of HSCT; Prialt for the management of severe chronic pain; and FazaClo LD and FazaClo HD tablets for the treatment-resistant schizophrenia, as well as Versacloz for treatment-resistant schizophrenia. The company also develops JZP-110, an investigational compound, which is in clinical development for the treatment of EDS in patients with narcolepsy; and JZP-386, a deuterium-modified analog of sodium oxybate products that is under pre-clinical research and development and is intended for the treatment of narcolepsy patients. In addition, it offers products in the areas of hematology and oncology drugs, such as Asparec, which is in Phase I clinical trial for the treatment of patients with ALL with E.coli asparaginase hypersensitivity; Defibrotide for the treatment of severe VOD; and Leukotac, an anti-CD25 monoclonal antibody that is in Phase III clinical trials and is intended for the treatment of steroid-refractory acute GvHD. The company is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hooper Suzanne SawochkaEVP and General CounselJul 08Option Exercise46.831,85386,77659,407Jul 10 08:09 PM
Keegan FintanEVP, Technical OperationsJul 08Option Exercise46.8346921,96333,741Jul 10 08:14 PM
Hooper Suzanne SawochkaEVP and General CounselJul 08Sale155.001,853287,21557,554Jul 10 08:09 PM
Keegan FintanEVP, Technical OperationsJul 08Sale155.001,991308,60531,750Jul 10 08:14 PM
COZADD BRUCE CChairman and CEOJul 08Sale155.005,000775,000597,067Jul 10 08:04 PM
WILSON KAREN JSVP, Finance & PAOJul 07Option Exercise27.462,50068,65026,169Jul 09 08:12 PM
WILSON KAREN JSVP, Finance & PAOJul 07Sale165.002,500412,50023,669Jul 09 08:12 PM
Mulligan SeamusDirectorJun 25Sale148.64476,9861,405,555Jun 26 08:21 PM
Mulligan SeamusDirectorJun 24Sale149.7049,9537,477,7491,405,602Jun 26 08:21 PM
Cox Russell J.EVP & Chief Operating OfficerJun 20Sale155.002,000310,00057,032Jun 24 07:06 PM
Keegan FintanEVP, Technical OperationsJun 17Sale150.003,750562,50033,272Jun 19 04:01 PM
COZADD BRUCE CChairman and CEOJun 10Sale142.345,000711,700602,067Jun 11 04:36 PM
Tobias Jeffrey KEVP, Research & Dev and CMOJun 09Option Exercise48.633,000145,89050,103Jun 11 06:30 PM
Tobias Jeffrey KEVP, Research & Dev and CMOJun 09Sale146.243,000438,72047,103Jun 11 06:30 PM
RIEDEL NORBERT GDirectorMay 28Sale142.4964491,7643,356May 29 07:27 PM
Hooper Suzanne SawochkaEVP and General CounselMay 27Option Exercise46.8366731,23657,802May 29 07:24 PM
Hooper Suzanne SawochkaEVP and General CounselMay 27Sale140.0066793,38057,135May 29 07:24 PM
COZADD BRUCE CChairman and CEOMay 13Sale128.925,000644,600606,810May 14 06:09 PM
Keegan FintanEVP, Technical OperationsMay 08Sale136.03750102,02337,772May 12 08:13 PM
Hooper Suzanne SawochkaEVP and General CounselApr 17Option Exercise46.8366731,23657,802Apr 21 07:59 PM
Winningham Rick EDirectorApr 17Sale140.0027,5003,850,00013,587Apr 21 07:55 PM
Hooper Suzanne SawochkaEVP and General CounselApr 17Sale140.0066793,38057,135Apr 21 07:59 PM
Tobias Jeffrey KEVP, Research & Dev and CMOApr 14Option Exercise53.883,000161,64651,103Apr 16 07:41 PM
Tobias Jeffrey KEVP, Research & Dev and CMOApr 14Sale128.543,000385,62048,103Apr 16 07:41 PM
Keegan FintanEVP, Technical OperationsApr 08Sale130.0075097,50038,522Apr 10 08:37 PM
COZADD BRUCE CChairman and CEOApr 08Sale123.185,000615,900611,810Apr 10 08:34 PM
Tobias Jeffrey KEVP, Research & Dev and CMOMar 10Option Exercise53.883,000161,63451,103Mar 12 06:06 PM
Tobias Jeffrey KEVP, Research & Dev and CMOMar 10Sale152.993,000458,97048,103Mar 12 06:06 PM
WILSON KAREN JSVP, Finance & PAOMar 07Option Exercise59.133,000177,39027,300Mar 11 08:26 PM
WILSON KAREN JSVP, Finance & PAOMar 07Sale155.043,888602,79623,412Mar 11 08:26 PM
Keegan FintanEVP, Technical OperationsMar 06Sale157.891,634257,99239,272Mar 06 07:01 PM
Mulligan SeamusDirectorMar 04Sale156.25550,00085,937,5001,455,555Mar 05 05:19 PM
Keegan FintanEVP, Technical OperationsMar 04Sale161.003,006483,96640,906Mar 06 07:01 PM
WILSON KAREN JSVP, Finance & PAOFeb 27Option Exercise46.8311,250526,83832,582Mar 03 08:14 PM
Tobias Jeffrey KEVP, Research & Dev and CMOFeb 27Sale165.463,000496,38041,777Mar 03 08:05 PM
COZADD BRUCE CChairman and CEOFeb 27Sale158.3625,0003,959,000600,754Mar 03 07:21 PM
Cox Russell J.EVP & Chief Commercial OfficerFeb 27Sale164.594,000658,36050,024Mar 03 07:10 PM
WILSON KAREN JSVP, Finance & PAOFeb 27Sale166.7711,2501,876,15021,332Mar 03 08:14 PM
FALBERG KATHRYN EEVP and CFOFeb 26Option Exercise7.3510,20474,999134,925Feb 27 08:08 PM
FALBERG KATHRYN EEVP and CFOFeb 12Sale157.002,000314,000124,721Feb 14 07:09 PM
Tobias Jeffrey KEVP, Research & Dev and CMOFeb 10Option Exercise46.832,560119,88547,337Feb 12 07:18 PM
Tobias Jeffrey KEVP, Research & Dev and CMOFeb 10Sale152.832,560391,24544,777Feb 12 07:18 PM
FALBERG KATHRYN EEVP and CFOJan 08Sale131.822,000263,640126,721Jan 10 08:26 PM
FALBERG KATHRYN EEVP and CFODec 11Sale120.503,000361,500128,721Dec 13 07:49 PM
Tobias Jeffrey KEVP, Research & Dev and CMODec 09Option Exercise46.831,32562,05046,102Dec 11 07:01 PM
Tobias Jeffrey KEVP, Research & Dev and CMODec 09Sale117.801,325156,08544,777Dec 11 07:01 PM
FALBERG KATHRYN EEVP and CFONov 13Sale100.883,000302,640131,372Nov 15 06:16 PM
Tobias Jeffrey KEVP, Research & Dev and CMONov 11Option Exercise46.832,373111,12846,778Nov 13 06:57 PM
Tobias Jeffrey KEVP, Research & Dev and CMONov 11Sale98.502,373233,74144,405Nov 13 06:57 PM
Tobias Jeffrey KEVP, Research & Dev and CMOOct 14Option Exercise46.835,000234,15049,405Oct 16 06:54 PM
Tobias Jeffrey KEVP, Research & Dev and CMOOct 14Sale82.625,000413,11844,405Oct 16 06:54 PM
FALBERG KATHRYN EEVP and CFOOct 09Sale83.103,000249,300134,372Oct 11 06:55 PM
COZADD BRUCE CChairman and CEOOct 08Sale88.584,000354,320625,647Oct 10 06:28 PM
FALBERG KATHRYN EEVP and CFOSep 11Sale87.523,000262,560137,372Sep 13 05:56 PM
COZADD BRUCE CChairman and CEOSep 10Sale87.595,000437,950629,647Sep 10 06:11 PM
Tobias Jeffrey KEVP, Research & Dev and CMOSep 09Option Exercise46.835,000234,15049,405Sep 10 06:03 PM
Tobias Jeffrey KEVP, Research & Dev and CMOSep 09Sale87.115,000435,55044,405Sep 10 06:03 PM
Cox Russell J.EVP & Chief Commercial OfficerSep 04Sale88.161,00088,16052,736Sep 04 05:48 PM
WILSON KAREN JSVP, Finance & PAOAug 30Sale87.622,000175,24021,075Sep 04 05:28 PM
Sohn Catherine A.DirectorAug 14Sale81.0264051,8535,610Aug 14 07:13 PM
FALBERG KATHRYN EEVP and CFOAug 14Sale81.023,000243,060140,372Aug 14 07:17 PM
Keegan FintanEVP, Technical OperationsAug 13Sale81.447,454607,02236,412Aug 14 07:54 PM
Winningham Rick EDirectorAug 13Sale81.861,07087,59041,087Aug 14 07:15 PM
MOMTAZEE JAMES CDirectorAug 13Sale81.861,07087,59017,315Aug 14 07:12 PM
ENRIGHT PATRICK GDirectorAug 13Sale81.861,07087,5903,430Aug 14 07:10 PM
BERNS PAUL LDirectorAug 13Sale81.861,07087,5903,430Aug 14 07:08 PM
COZADD BRUCE CChairman and CEOAug 13Sale81.865,000409,300634,647Aug 13 09:00 PM
Tobias Jeffrey KEVP, Research & Dev and CMOAug 12Option Exercise46.837,500351,22551,905Aug 13 09:03 PM
Keegan FintanEVP, Technical OperationsAug 12Sale80.831,21297,96643,866Aug 14 07:54 PM
Tobias Jeffrey KEVP, Research & Dev and CMOAug 12Sale80.777,500605,77544,405Aug 13 09:03 PM
O'Keefe Kenneth WDirectorAug 08Sale81.32261,21221,241,7600Aug 09 05:02 PM
Cox Russell J.EVP & Chief Commercial OfficerAug 01Sale76.222,000152,44057,046Aug 02 08:30 PM